Sign in to continue:

Monday, March 2nd, 2026

Great Elm Capital Corp. Announces Full Redemption of 5.875% Notes Due 2026 Effective March 31, 2026

Great Elm Capital Corp. Announces Full Redemption of 5.875% Notes Due 2026

Key Highlights:

  • Great Elm Capital Corp. (“the Company”) has issued a formal notice of redemption for its 5.875% Notes due 2026 (CUSIP No. 390320 604).
  • The Company will redeem the entire \$20,000,000 aggregate principal amount of the outstanding Notes.
  • The redemption date is March 31, 2026.
  • Holders will receive 100% of the principal amount per Note (\$25.00 per Note), plus any accrued and unpaid interest up to, but excluding, the redemption date.
  • Interest on the Notes will cease to accrue after March 31, 2026.
  • The next scheduled interest payment date is also March 31, 2026, and the company does not expect any accrued and unpaid interest to be outstanding as of the redemption date.
  • Notes purchased after March 15, 2026, and before March 31, 2026 will not be entitled to any accrued and unpaid interest.
  • Notes held in book-entry form will be redeemed through The Depository Trust Company procedures.
  • Physical notes should be surrendered to Equiniti Trust Company, LLC, the Trustee and Paying Agent, at their Mendota Heights, MN address.
  • Backup withholding may apply if holders fail to provide taxpayer identification details.

Investor Impact & Price-Sensitive Information:

  • This full redemption signals a significant corporate action, potentially affecting the Company’s debt profile and liquidity position.
  • Investors holding the Notes should note the certainty of redemption and the cessation of interest accrual after March 31, 2026.
  • The redemption is at par, with no premium, which may impact fixed-income investors seeking yield or capital appreciation.
  • Shareholders should consider the implications for the Company’s future capital structure—removing this debt may affect both risk and return expectations for Great Elm Capital Corp.’s equity.
  • The announcement may influence market sentiment regarding the Company’s financial health, strategic direction, and use of capital.
  • Tax considerations are important, as holders must provide appropriate IRS forms to avoid backup withholding on redemption payments.

Action Steps for Holders:

  • Ensure Notes are registered in your name by March 15, 2026 to receive any final interest payment.
  • Prepare to surrender Notes for payment after the redemption date, either via DTC procedures (for book-entry holders) or by mailing them to Equiniti Trust Company, LLC.
  • Complete and submit IRS Form W-9 or W-8 to avoid backup withholding.
  • Contact Equiniti Trust Company, LLC at 1–800-937-5449 for questions or assistance regarding the redemption process.

Additional Information:

  • No representation is made regarding the accuracy of the CUSIP numbers listed in the notice.
  • All amounts withheld under backup withholding rules can be credited or refunded if the required information is provided to the IRS.
  • Holders are advised to consult tax advisors regarding the withholding and other tax consequences of the redemption.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are urged to review the official redemption notice, consult their financial advisors, and consider their own circumstances before making any investment decisions. The information provided is based on public filings and may be subject to change. Great Elm Capital Corp. and its agents are not responsible for errors or omissions in this summary.

View Great Elm Capital Corp. Historical chart here



NovoCure Limited 8-K SEC Filing February 2026: Company Information, Address, and NASDAQ Listing Details

NovoCure Limited Files Form 8-K: Medicare Billing Privileges Reinstated Key Points: NovoCure Limited (Nasdaq: NVCR) has filed a Form 8-K Current Report with the U.S. Securities and Exchange Commission dated February 24, 2026. The...

LyondellBasell Industries N.V. 2025 Annual Report: Business Segments, Investments, and Financial Highlights (10-K Filing)

Key Financial and Corporate Highlights Corporate Structure and Headquarters: LyondellBasell Industries N.V. is incorporated in the Netherlands but maintains principal business operations in Houston, Texas, and London, UK. The company is classified under Industrial...

Semnur Pharmaceuticals, Inc. 2024 Annual Report: Non-Opioid Pain Management Innovations & SP-102 Clinical Results

Semnur Pharmaceuticals, Inc. 2025 Annual Report: Key Highlights for Investors Semnur Pharmaceuticals, Inc. 2025 Annual Report: Key Highlights for Investors Overview Semnur Pharmaceuticals, Inc. (Nasdaq: SMNR) has released its Annual Report on Form 10-K...

   Ad